Navigation Links
MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors
Date:1/6/2011

ROCKVILLE, Md., Jan. 6, 2011 /PRNewswire/ --  MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.  MGAH22 is an Fc-optimized monoclonal antibody developed by MacroGenics which has been shown, in pre-clinical studies, to reduce tumor growth significantly in a broad panel of HER2-expressing tumors.

"We are excited to have begun clinical testing of MGAH22, a next generation antibody that may have wide application in cancer treatment," stated Dr. Scott Koenig, President and CEO of MacroGenics.  "MGAH22 is the first Fc-engineered antibody therapeutic from our oncology pipeline to enter clinical development and represents a major milestone for MacroGenics.  Our pre-clinical studies suggest that MGAH22 may provide significant differentiation from the other HER2-targeted immunotherapeutics, including the ability to treat tumors with relatively low levels of HER2 expression."

This open-label, multi-dose, single-arm, multi-center Phase I, dose-escalation study is being conducted to define the toxicity profile, maximum tolerated dose, pharmacokinetics, immunogenicity, and potential antitumor activity of MGAH22 in patients with refractory HER2-positive breast cancer and patients with other carcinomas that overexpress HER2 for whom no standard therapy is available.  Additional information on the clinical trial can be found at: http://www.clinicaltrials.gov/ct2/show/NCT01148849.

Three internationally recognized investigators are participating in this trial, including: Dr. Howard A. Burris, III from the Sarah Cannon Research Institute, Dr. Giuseppe Giaccone from the National Cancer Institute and Dr. Yung-Jue Bang from Seoul National University Hospital.
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
2. MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
3. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
4. Paulo F. Costa Joins MacroGenics Board of Directors
5. MacroGenics Appoints New Vice President of Business Development
6. MacroGenics Raises $25M in Series D-2 Financing
7. Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors
8. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
9. Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
10. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
11. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
(Date:12/24/2014)... December 23, 2014 Earlier this year in ... director of the Adult Stem Cell Technology Center, LLC ( ... appreciated unique property of adult tissue stem cells. His ... Past, Important for the Future,” embodied the essence of his ...
(Date:12/24/2014)... December 23, 2014 The report ... its definition, classification, application and industry overview. This ... product cost structure. Production is separated by regions, ... raw materials, equipment, downstream client survey, marketing channels, ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... (OTCBB:MYMX) announced today that its company information ... Market Access Program, an,information distribution service that ... company information disseminated to users of,Standard & ... be made,available through this program includes share ...
... Comprehensive Clinical Picture, Improves,Patient-Physician Communications, KING ... A patients who,use Helixate(R) FS, Antihemophilic Factor ... treatment progress in real time,thanks to the ... system recently introduced by CSL Behring. The ...
... President of Commercial Operations,and James Briggs Senior Vice ... 25 Ikaria Holdings, Inc., a fully,integrated critical ... key executives. Stephen A. Ross was appointed Senior ... named Senior Vice,President for Human Relations., Daniel ...
Cached Biology Technology:Mymetics Corporation Information to be Available Through Standard & Poor's Market Access Program 2CSL Behring's Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients 2CSL Behring's Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients 3CSL Behring's Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients 4Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership 2
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
(Date:1/22/2015)... , Jan. 22, 2015 Infinisource has launched its new ... G2 model. The G2 sets a higher standard for collecting ... capital management solution. With plug-and-play installation, touch screen interface and ... provides a robust time collection solution for the small to ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2Infinisource's NXG series sets new time clock standard 2
... Dalhousie University in Nova Scotia have identified a key ... growth if their findings are confirmed. In ... journal of the American Association for Cancer Research, lead ... Biochemistry and Molecular Biology and Pathology, and Canada Research ...
... it,s on to proteins, a much more daunting task. There ... molecules in our bodies. Many of these hold keys to ... Northwestern University chemical biologist Neil Kelleher has developed a new ... molecules quickly. Many have been skeptical that such an approach, ...
... major public symposium at Boston College will bring together four ... contributions of the physical and social sciences to a contemporary ... Liberal Arts University Why It Matters to Us All, ... the Liberal Arts, takes place today at the University,s main ...
Cached Biology News:Key driver of metastasis identified 2So many proteins, so much promise 2So many proteins, so much promise 3Science in the liberal arts university 2
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
...
...
Biology Products: